Haldol

Haldol is the brand name for haloperidol, an oral antipsychotic medication marketed in the European Union. Specific strength and formulation details are not disclosed, and the product is prescription‑only. Haloperidol belongs to the butyrophenone class and works as a dopamine D2 receptor antagonist, helping to control symptoms of psychosis and certain movement disorders. It is listed under ATC code N05AD01 for adult patients.

Haloperidol (Haldol) is indicated for several psychiatric and neurological conditions where dopamine blockade is therapeutic.

- Schizophrenia, including acute exacerbations and maintenance therapy, where haloperidol helps reduce hallucinations, delusions, and thought disorder. - Acute psychotic episodes unrelated to schizophrenia, such as drug‑induced or brief psychotic disorder, for short‑term symptom control. - Manic episodes of bipolar disorder, used as an adjunct to mood stabilizers to lessen elevated mood, hyperactivity, and impulsivity. - Tourette syndrome and other tic disorders, providing reduction in motor and vocal tics when other treatments are insufficient. - Severe agitation or aggression requiring rapid control, administered in hospital settings to calm patients safely.

Haloperidol may cause a range of adverse effects, which are generally categorized by frequency and clinical significance.

Common: - Drowsiness or sedation, often most noticeable at treatment initiation. - Extrapyramidal symptoms such as tremor, rigidity, or akathisia, reflecting dopamine blockade in the basal ganglia. - Dry mouth and constipation, resulting from anticholinergic effects. - Blurred vision or ocular discomfort, which may affect near tasks. - Weight gain or increased appetite, potentially contributing to metabolic changes. - Nausea or vomiting, usually mild and transient. - Orthostatic hypotension, causing light‑headedness upon standing.

Serious: - Neuroleptic malignant syndrome, a rare but life‑threatening reaction characterized by fever, muscle rigidity, autonomic instability, and altered mental status. - Tardive dyskinesia, characterized by involuntary movements of the face, tongue, or limbs after prolonged use, which may be irreversible. - Significant cardiac arrhythmias, including QT interval prolongation that can predispose to torsades de pointes.

When prescribing haloperidol, clinicians consider several precautionary measures to minimize risk and ensure appropriate use.

- Assess patient history for cardiovascular disease, as haloperidol may affect heart rhythm. - Evaluate for prior extrapyramidal reactions or movement disorders before initiating therapy. - Use the lowest effective dose, especially in elderly patients, to reduce sedation and fall risk. - Monitor for signs of neuroleptic malignant syndrome during the first weeks of treatment. - Consider pregnancy and lactation status; haloperidol crosses the placenta and may be present in breast milk. - Review liver and kidney function, adjusting dose if significant impairment is present.

Haloperidol can interact with other medicines, altering its effectiveness or increasing the risk of adverse effects.

Avoid: - Other dopamine antagonists or antipsychotics, which may amplify extrapyramidal side effects. - Medications that prolong the QT interval, such as certain antiarrhythmics, macrolide antibiotics, or antipsychotics, increasing cardiac risk. - Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin) that can raise haloperidol plasma levels.

Use with caution: - CNS depressants like benzodiazepines or opioids, which may enhance sedation. - Anticholinergic agents, as they can mask early signs of extrapyramidal symptoms. - Lithium, because combined use may increase neurotoxicity.